{"contentid": 487928, "importid": NaN, "name": "AstraZeneca prevails in patent litigation on Symbicort", "introduction": "The US District Court for the Northern District of West Virginia has decided in favour of AstraZeneca in litigation against Mylan Pharmaceuticals and Kindeva Drug Delivery, determining that asserted claims in three of AstraZeneca\u00e2\u0080\u0099s patents protecting Symbicort (budesonide/formoterol) in the US are not invalid.", "content": "<p>The US District Court for the Northern District of West Virginia has decided in favour of AstraZeneca (LSE: AZ N) in litigation against Mylan Pharmaceuticals and Kindeva Drug Delivery, determining that asserted claims in three of AstraZeneca&rsquo;s patents protecting Symbicort (budesonide/formoterol) in the US are not invalid.</p>\n<p>Symbicort recorded $2.7 billion global sales for AstraZeneca in 2020, with $1.02 billion generated in the USA.</p>\n<p>Ruud Dobber, executive vice president, BioPharmaceuticals Business Unit, said: &ldquo;AstraZeneca is pleased with the Court&rsquo;s decision, and we maintain full confidence in the strength of our intellectual property rights protecting Symbicort.&rdquo;</p>\n<p><strong>Symbicort US patent trial</strong></p>\n<p>In October 2018, AstraZeneca initiated litigation against Mylan, which is now operating under the name Viatris (NYSE: VTRS) following the merger with Pfizer&rsquo;s Upjohn unit, and subsequently against 3M Company (3M) asserting infringement of various US patents covering Symbicort. In July 2020, Kindeva was added as a defendant in the action. 3M was voluntarily dismissed from the case.</p>\n<p>In September 2020, Mylan and Kindeva stipulated to patent infringement to the extent that the asserted patent claims were found to be valid and enforceable, but reserved the right to seek a vacatur of the stipulation if the US Court of Appeals for the Federal Circuit reverses or modifies the District Court&rsquo;s claim construction. At trial, Mylan and Kindeva contended that each asserted patent claim is invalid under the US patent laws.</p>", "date": "2021-03-03 11:49:00", "meta_title": "AstraZeneca prevails in patent litigation on Symbicort", "meta_keywords": "AstraZeneca, Patent, Litigation, Symbicort, Mylan, Kindeva, Viatris, District Court", "meta_description": "AstraZeneca prevails in patent litigation on Symbicort", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 11:49:04", "updated": "2021-03-03 11:56:48", "access": NaN, "url": "https://www.thepharmaletter.com/article/astrazeneca-prevails-in-patent-litigation-on-symbicort", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "patent_trademark_legal_big.jpg", "image2id": "patent_trademark_legal_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Respiratory and Pulmonary", "topic_tag": "Focus On, Legal, Patents & Trademarks", "geography_tag": "UK, USA", "company_tag": "AstraZeneca, Mylan, Viatris", "drug_tag": "Symbicort", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 11:49:00"}